A single diagnostic method — the self-reported questionnaire — is misclassifying roughly nine out of ten adults with Bardet-Biedl syndrome who have severe hyperphagia. Rhythm Pharmaceuticals’ data presented at the 2026 European Congress of Endocrinology puts that failure rate at 92.3%: nearly every patient interviewed by a clinician was reclassified upward in hyperphagia severity compared to what they reported on paper. That is not a measurement nuance. That is a structural underdiagnosis problem with direct commercial consequences for a company whose entire rare-obesity franchise depends on physicians recognizing and acting on hyperphagia as a treatable, drug-eligible condition.
The more immediately quantifiable story is the French early-access cohort. Among 25 adults with acquired hypothalamic obesity who reached 12 months on setmelanotide, mean BMI fell 16.9% from baseline. At nine months — the cohort’s sweet spot statistically — the reduction hit 19.6%. These are not marginal shifts in a population where standard obesity pharmacotherapy routinely fails because the mechanism is hypothalamic, not peripheral. The TRANSCEND Phase 3 post-hoc adds further weight: Lipid Accumulation Product dropped 36.4 points versus essentially flat on placebo, and the Fatty Liver Index fell 24.2 versus a placebo increase of 4.4. Cardiometabolic composite scores moved in the same direction across every index tested. The drug is doing something systemically, not just on the scale.
Strategically, Rhythm is executing a deliberate label-expansion logic. Setmelanotide entered the market on genetic obesity indications — MC4R pathway defects, BBS, POMC deficiency. Acquired hypothalamic obesity from craniopharyngioma is a mechanistically adjacent but commercially distinct population, one that payers and neurologists have historically treated as an intractable sequela rather than a drug target. The French program is functioning as a pre-approval evidence engine in Europe, and the cardiometabolic data give Rhythm a payer argument that goes beyond weight: metabolic syndrome z-scores, visceral adiposity, hepatic steatosis markers. That reframes setmelanotide from a niche orphan drug into something that competes on outcomes payers already pay attention to.
The single consequence worth tracking is European reimbursement authority response to the French real-world dataset — specifically whether HAS or NICE treat 12-month BMI reductions of 17% plus multi-index cardiometabolic improvement as sufficient for a positive benefit assessment in acquired HO, a decision that would set the template for every other European market Rhythm enters.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
